The findings of controlled trials on use of intravenous immunoglobulin G (IV IgG) to treat myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) are generally viewed as representing mixed results. On detailed review, a clearer picture emerges, which suggests that the potential therapeutic value of this intervention has been underestimated.
HEALTH Learn about M.E. – free CPD training for health professionals in the UK GENERAL New support for…
For many years the definition of ME/CFS has been wrongly placed in the medical textbook by Kumar &…
ME/CFS: Exercise goals should be set by patients and not driven by treatment plan, says NICE NICE ME.CFS…
Doctors with ME heartily welcome these new guidelines. In particular we welcome the emphasis on ME being a…
ME/CFS strikes 1 in 250 of us. It is a devastating illness, more disabling than angina or multiple sclerosis. Three quarters…
Over a hundred academics, patient groups, lawyers, and politicians have now signed an open letter to the Lancet calling on…